Screener
Taysha Gene Therapies, Inc. TSHA Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue-Miss by $755.6K
EPS-$0.10Beat by $0.03
Revenue estimate$755.6K
EPS estimate-$0.13
“During the third quarter, we continued to make strong progress across our clinical, manufacturing and commercial readiness activities as we advance toward a potential BLA submission for TSHA-102. With all patients dosed and having cleared the acute post-dosing safety monitoring period in our REVEAL pivotal and ASPIRE trials with no severe treatment-related serious adverse events or dose-limiting toxicities observed across all studies, our focus now turns to delivering a robust dataset to support our planned BLA submission and further establish the potential of TSHA-102 to address the significant unmet need in Rett syndrome. In parallel, we achieved an important manufacturing milestone with the successful completion of our BLA-enabling PPQ manufacturing campaign, which met the predefined acceptance and comparability criteria previously reviewed with FDA. Importantly, the results further demonstrated our ability to consistently manufacture high-quality product at commercial scale, including an encouraging single-digit empty capsid percentage, a key indicator of product quality that contributes to patient safety. Looking ahead, we believe the first half of 2027 could be a transformative period for Taysha with our plan to report data from the six-month interim analysis of our REVEAL pivotal trial along with expected FDA feedback on our BLA submission pathway, and the anticipated nomination of a second gene therapy development program with a high unmet medical need and robust commercial opportunity as we begin building a broader CNS genetic medicine franchise.”
Next report
Date not yet announcedVersus estimates
Revenue
Diluted EPS
FAQ
- When did Taysha Gene Therapies, Inc. report Q3 2026 earnings?
- Taysha Gene Therapies, Inc. (TSHA) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Taysha Gene Therapies, Inc.'s Q3 2026 revenue and EPS?
- Taysha Gene Therapies, Inc. reported revenue of - and eps of $-0.10 for Q3 2026.
- Did Taysha Gene Therapies, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $755.6K by $755.6K. EPS beat the consensus estimate of $-0.13 by $0.03.
- How did Taysha Gene Therapies, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 11.1% from $-0.09.
- Where can I find Taysha Gene Therapies, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-456974) and the 10-Q periodic report (0001193125-26-456949) directly on SEC EDGAR. The filing index links above go to sec.gov.
